PubMed Health⌕ Search

Biomedical subjects

E Carmina

Publications and source records attributed to E Carmina.

69 records · Page 4Linked to original sources
PubMed1981

Nomifensine in the diagnosis of hyperprolactinemia.

The Authors try out Nomifensine, a new antidepressant drug which activates dopaminergic neurotransmission by inhibiting the DA reuptake. The patients tested consisted of: 11 normoprolactinemic control patients; 2 hyperprolactinemic patients with sellar alterations; 5 hyperprolactinemic patients with no radiological alterations; 6 patients with micro-adenomas; 1 patient with macroadenoma. We administered 200 mg of the drug orally and then took blood samples for 4 hours. We conclude positively that nomifensine is a useful complement to the diagnostic collage for discriminating between tumorous and non-tumorous hyperprolactinemia, and we look forward to further research which will increase the literature on this subject and which will explain some mechanisms and effects which have not yet been clarified, and we hope that this research will further prove the importance of the test.

Adenoma↗
PubMed1979

Effect of the acute administration of haloperidol and pimozide on plasma GH levels in acromegaly.

In 11 untreated acromegalic patients the plasma GH levels were determined after the acute administration of bromocriptine, haloperidol, pimozide (only in 8 patients) and of placebo. A 50% or more suppression of the basal GH levels was arbitrarily defined as a positive response to bromocriptine. Five patients displayed a negative response to bromocriptine. Of these, 4 responded to both antidopaminergic drugs. We conclude that the acute administration of antidopaminergic drugs reduces the GH secretion in some bromocriptine-insensitive acromegalic patients. Therapeutical implications will require further studies.

Acromegaly↗
PubMed1976

[Changes in blood sugar, and insulin levels induced by somatostatin in normal, diabetic and acromegalic subjects].

The effect of somatostatin on plasma sugar and insulin levels was determined in 8 normal, 7 diabetic and 5 acromegalic subjects. An absolute fall in blood sugar values on the order of about 20% was noted, though during administration of the drug only, in all cases. Normal and diabetic subjects also showed an approximately 40% decrease in blood insulin, whereas no such fall was observed in the acromegalic. In spite of the simultaneous fall in insulin levels, it was clear that the reduction in blood sugar was ascribable to a drug-induced block of glucagon secretion. The part possibly played by somatostatin in the regulation of glucide homeostasis is examined in the light of these results.

Acromegaly↗
PubMed1976

Incomplete type I male pseudohermaphroditism.

The observation of a case of male pseudohermaphroiditism offered the opportunity for an analytical review of this pathology. Clinical features and failure to respond to prolonged testosterone treatment allowed this case to be included in the group characterized by androgen resistance of which a recent classification distinguishes various types on the basis of phenotypic and hormonal features. Incomplete virilization of the external genitals and high testosterone and LH plasma levels were evidence in favour of the conclusion that the case should be classified as incomplete male type I pseudohermaphroditism.

Adult↗
PubMedDate not supplied

Late-onset 3 beta-ol-hydroxysteroid-dehydrogenase deficiency: prevalence, clinical presentation and endocrine pattern.

3 patients with late-onset 3 beta-HSD deficiency are described. They presented increased DHEAs/delta 4 ratio either in basal conditions or after ACTH stimulation. All patients were hirsute but only one had increased serum values of delta 4 and total testosterone. However, all patients presented increased serum levels of free testosterone. Two patients had normal menstrual cycles and in one case a secondary PCO was found.

3-Hydroxysteroid Dehydrogenases↗
PubMedDate not supplied

[Normalization of the GH response to L-DOPA in acromegalics after treatment with bromocriptine].

The plasma GH response to the L-dopa test (500 mg per os) has been assessed in 7 acromegalics who had never been treated before. Whereas three patients showed an increase in plasma GH, the other four presented a paradoxical response with a significant reduction in plasma GH levels. All subjects were put on to treatment with bromocryptin (10 mg/die). Three months later it was noted that only the four subjects with paradoxical response to L-dopa responded positively to bromocryptin treatment (at least 50% reduction in plasma GH). The L-dopa test was repeated in these four patients. In three of them who presented basal levels of GH lower than 10 ng/ml the L-dopa response curve was found to be reversed. It is concluded that in responsive patients, bromocryptin not only reduces GH levels but also normalizes the response to certain stimuli such as L-dopa.

Acromegaly↗
PubMedDate not supplied

Altered regulation of insulin-like growth factor binding protein-1 in patients with polycystic ovary syndrome.

OBJECTIVE: Insulin-like growth factor (IGF-I) action is influenced by circulating as well as tissue levels of its binding proteins. Because serum IGF binding protein-1 (IGFBP-1) levels have been found to be decreased in patients with polycystic ovary syndrome (PCOS), we tested the hypothesis that regulation of IGFBP-1 secretion may be different in patients with PCOS compared with normal women. METHODS: We studied 15 normal ovulatory women and 15 women with PCOS of similar age (21 +/- 1 and 22 +/- 1 years, respectively). All subjects were studied after an overnight fast between days 5-8 after spontaneous or progestin-induced menses. Perturbations included the administration of insulin intravenously, maintenance of a euglycemic clamp, and, in a subsequent cycle, the administration of a long-acting somatostatin analogue (octreotide, 100 micrograms) given subcutaneously. Blood samples were collected before treatment, every 15 minutes for 6 hours after insulin, and every 30 minutes for 3 hours after octreotide administration. Serum levels of IGF-I, IGFBP-1, IGFBP-3, and insulin were measured by specific immunoassays. RESULTS: Compared with the controls, patients with PCOS had significantly higher insulin levels, similar IGF-I and IGFBP-3 levels, and significantly lower IGFBP-1. Insulin did not change serum IGF-I levels in either group, although a significant decrease in IGFBP-1 levels occurred in normal women but not in patients with PCOS. Octreotide treatment also did not change serum IGF-I levels in either group, but serum insulin levels decreased significantly and IGFBP-1 levels increased significantly in both groups; this response was significantly greater in controls. CONCLUSIONS: Our data are compatible with the notion that regulation of IGFBP-1 is altered in women with PCOS and that several factors may be involved.

Adult↗